StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Pfizer (PFE) Phase 3 Trial of Revatio in Newborns with PPHN Did Not Meet its Primary Efficacy Endpoint
June 28, 2019 4:06 PM
Pfizer Inc. (NYSE: PFE) announced today that a Phase 3 study to assess the efficacy and safety of intravenous (IV) ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Corporate News
FDA
Hot FDA News
Next Articles
Pfizer (PFE) Reports Positive Top-Line Results from Phase 4 Study of Crisaborole Ointment
July 1, 2019 8:04 AM
Pfizer Announces Results from Phase 3 Trial of Revatio® (Sildenafil Citrate) in Newborns with Persistent Pulmonary Hypertension
June 28, 2019 4:05 PM